Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PJ-01
- Development stage
- Preclinical
- Lead developer
- Parabon NanoLabs
- Modality
- Nanoparticles → Drug Delivery Systems
01
Overview
**PJ-01** is an Essemblix-engineered, prostate cancer-targeted docetaxel therapeutic developed by Parabon NanoLabs with scientific input and testing support from Janssen. The single investigational compound was designed to preferentially deliver the microtubule-stabilizing chemotherapy payload docetaxel to prostate tumor cells and includes undisclosed moieties intended to increase prostate cancer-cell responsiveness, with the objective of improving antitumor activity while reducing systemic toxicity. The targeting ligand, carrier architecture, linker chemistry, sensitizing components, dosage form, route, and clinical-stage progression have not been publicly disclosed. ([www03.parabon-nanolabs.com](https://www03.parabon-nanolabs.com/news-events/2012/12/Parabon_NanoLabs-NSF_Janssen_TECP_Award.html))
Beyond the preview
Go deeper on PJ-01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PJ-01.